Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…Abstract Number: 0612 • ACR Convergence 2023
COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study
Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…Abstract Number: 1536 • ACR Convergence 2023
The Impact of COVID-19 Vaccination on ANCA Vasculitis Hospitalisations: A Perspective from Sydney Australia
Background/Purpose: COVID-19 vaccination can trigger a range of inflammatory and auto-immune phenomena, potentially including AAV. There are several international case reports of de novo and…Abstract Number: 1823 • ACR Convergence 2023
Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia
Background/Purpose: Immunothrombosis is a critical pathological feature of fulminant COVID-19 pneumonia in which immunosuppression with common immunomodulatory agents such as corticosteroids, IL-6 receptor blockers, and…Abstract Number: 2282 • ACR Convergence 2023
Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19
Background/Purpose: The SARS-CoV2 pandemic reopened the unresolved question of whether and how a viral infection can trigger flares of immune-mediated inflammatory diseases such as systemic…Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…Abstract Number: 0719 • ACR Convergence 2023
Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study
Background/Purpose: Polymyalgia rheumatica (PMR) incidence peaks in individuals between 70 and 80 years of age; this same group is also at increased risk of complications…Abstract Number: 1609 • ACR Convergence 2023
Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study
Background/Purpose: SARS-CoV-2 infection has been increasingly recognized for its potential neurological manifestations. Fibromyalgia (FM) patients, who already experience neuropathic pain, may be particularly vulnerable to…Abstract Number: 1824 • ACR Convergence 2023
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Background/Purpose: Acknowledgment: Contributed on behalf of the National COVID Cohort Collaborative (N3C) ConsortiumIndividuals with rheumatologic diseases (RD) are at higher risk for severe COVID-19 compared…Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…Abstract Number: 0219 • ACR Convergence 2023
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…Abstract Number: 0810 • ACR Convergence 2023
Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic
Background/Purpose: The COVID-19 pandemic prompted a rapid transition to increased telehealth utilization, with many rheumatology providers replacing in-person clinical visits with telehealth visits or expanding…Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…Abstract Number: 1831 • ACR Convergence 2023
Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
Background/Purpose: Fibromyalgia (FM) symptoms fluctuate, with exacerbation commonly associated with stressors. The COVID-19 pandemic was a cause of prolonged stress due to factors such as…Abstract Number: 2300 • ACR Convergence 2023
Outcomes of COVID-19 Before and During the Omicron Variant Period in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study Using the TriNetX Network
Background/Purpose: The global dominance of the SARS-CoV-2 Omicron variant ensued shortly after its initial identification in South Africa on November 24, 2021. The outcomes of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 35
- Next Page »